

Polyherbal Formulations as Hepatoprotective Candidates against Paracetamol-Induced Liver Injury: Mechanistic Review and Quality Considerations

Santosh G. Kathwate^{*1}, Dr. Ravi U. Kurhade², Dr. Manoj H. Dev³,
Baliram A. Lawate⁴, Vaibhavi V. Mali⁵

¹M. Pharm Final Year Student, Department of Pharmacology MDA School of Pharmacy, Kolpa, Latur, Maharashtra

²Principal, Department of Pharmaceutics MDA School of Pharmacy, Kolpa, Latur, Maharashtra

³Professor, Department of Pharmacology MDA School of Pharmacy, Kolpa, Latur, Maharashtra

⁴Assistant Professor, Department of Pharmaceutics MDA School of Pharmacy, Kolpa, Latur, Maharashtra

⁵Assistant Professor, Department of Pharmaceutics MDA School of Pharmacy, Kolpa, Latur, Maharashtra

Corresponding Author: Santosh G. Kathwate

Email Id: santhoshsantosh94859@gmail.com

Abstract: Paracetamol-induced liver injury remains a central experimental and clinical model for studying dose-dependent hepatotoxicity. The toxic mechanism involves formation of N-acetyl-p-benzoquinone imine, glutathione depletion, oxidative stress, mitochondrial dysfunction, inflammatory amplification and hepatocyte death. Polyherbal formulations are increasingly explored because plant constituents may provide antioxidant, anti-inflammatory, membrane-stabilizing and detoxification-supportive effects. However, the scientific value of polyherbal research depends on botanical authentication, marker-based standardization, controlled extraction, dose uniformity, safety review and appropriate endpoint selection. This review integrates the thesis material into a journal-style narrative covering paracetamol metabolism, hepatotoxic mechanisms, selected herbal markers, Quality-by-Design principles, preclinical evaluation methods and translational limitations. The review concludes that polyherbal hepatoprotection should be interpreted cautiously and should be supported by convergent biochemical, oxidative and histopathological evidence.

Keywords: acetaminophen toxicity; paracetamol; hepatoprotection; polyherbal formulation; NAPQI; oxidative stress; silymarin; phytoconstituents; Quality by Design

I. INTRODUCTION

Drug-induced liver injury is a major concern in pharmacology and toxicology because the liver performs xenobiotic metabolism, detoxification, protein synthesis and bile formation. Paracetamol, also known as acetaminophen, is particularly important because it is therapeutically useful but can cause predictable hepatotoxicity after overdose [1-17]. This dual nature makes it suitable for mechanistic toxicology studies and hepatoprotective screening.

Plant-based medicines are traditionally used for liver support, yet modern scientific evaluation requires more than ethnomedicinal history. A formulation intended for hepatoprotection must demonstrate reproducible identity, controlled phytochemical quality, acceptable safety and measurable protection in relevant models. Polyherbal formulations add further complexity because multiple botanical materials and marker constituents may interact during extraction, storage, dosing and biological testing.



The thesis material supporting this review emphasizes mechanistic interpretation, QbD-based standardization and connected endpoint analysis. In this article, the information is reorganized into a review structure suitable for manuscript preparation, with emphasis on scientific caution and validation needs.

II. REVIEW APPROACH

This narrative review was prepared from the supplied thesis chapters, including introduction, literature review, drug profile, Quality by Design, materials and methods, results framework, conclusion and Vancouver-style references. The literature themes were organized around paracetamol toxicity, oxidative stress, inflammation, mitochondrial injury, hepatoprotective phytoconstituents, preclinical assay methods, and quality standardization.

III. MECHANISTIC BASIS OF PARACETAMOL-INDUCED LIVER INJURY

At therapeutic doses, paracetamol is mainly metabolized by glucuronidation and sulfation. A smaller fraction undergoes cytochrome P450-mediated oxidation to NAPQI. Under overdose conditions, conjugation pathways become saturated, NAPQI generation increases and hepatic glutathione stores are depleted. When glutathione is insufficient, NAPQI binds cellular proteins and initiates mitochondrial oxidative stress and hepatocellular injury [7-17].

Mitochondrial dysfunction is central to the injury cascade. Oxidative stress, impaired ATP generation, mitochondrial permeability changes and downstream inflammatory signals contribute to necrosis. The resulting enzyme leakage is detected as increased ALT and AST, while disturbed excretory function may elevate ALP and bilirubin. Histopathology provides anatomical confirmation of necrosis, congestion, inflammatory infiltration and loss of hepatic architecture.

Paracetamol Metabolism and Liver Injury Pathway



Original schematic prepared for thesis drafting; replace with final approved figure if required.

Figure 1. Paracetamol metabolism and liver injury pathway.

Table 1. Mechanistic sequence of paracetamol hepatotoxicity and relevant endpoints

Toxic event	Biological effect	Suggested measurable endpoint
NAPQI formation	Reactive metabolite load and protein adduct formation	Dose documentation; mechanistic interpretation
GSH depletion	Loss of detoxification capacity	Reduced glutathione estimation
Mitochondrial oxidative stress	Lipid peroxidation and energy failure	MDA, SOD, catalase, GPx
Membrane injury	Leakage of intracellular enzymes	ALT and AST
Functional/excretory stress	Bile flow or bilirubin handling disturbance	ALP and bilirubin
Tissue necrosis	Loss of hepatic architecture	Histopathology and injury score




IV. RATIONALE FOR POLYHERBAL HEPATOPROTECTION

The theoretical advantage of a polyherbal formulation is its ability to address multiple toxic events. A single compound may influence one major pathway, whereas a combination of phytoconstituents may collectively support antioxidant defense, inflammatory control, membrane stability and detoxification. This possibility should be treated as a hypothesis until confirmed experimentally.

The drug profile section of the thesis lists paracetamol as the toxic challenge agent, N-acetylcysteine as a clinical antidote context, silybin/silymarin as a standard hepatoprotective comparator and herbal markers such as curcumin, andrographolide, glycyrrhizin, quercetin and gallic acid. These markers provide a chemical basis for analytical standardization and mechanistic discussion.

Multi-target Polyherbal Hepatoprotection Concept



Pen-style concept map; arrows show hypothesized support, not confirmed clinical efficacy.

Figure 2. Multi-target polyherbal hepatoprotection concept.

Table 2. Selected drug and phytochemical markers relevant to hepatoprotection

Component	Chemical/biological role	Relevance to liver injury model
Paracetamol	Challenge agent	Produces NAPQI-linked hepatocellular injury at toxic doses
N-acetylcysteine	Glutathione precursor and clinical antidote context	Supports NAPQI detoxification and GSH restoration
Silybin / silymarin	Reference hepatoprotective marker	Antioxidant and membrane-supportive comparator
Curcumin	Polyphenolic anti-inflammatory marker	May support inflammatory and oxidative stress control
Andrographolide	Diterpene lactone	May contribute anti-inflammatory and antioxidant activity
Glycyrrhizin	Triterpenoid saponin marker	May support membrane and inflammatory regulation; safety must be considered
Quercetin	Flavonol	Radical scavenging and redox-supportive marker




Gallic acid	Phenolic acid	Antioxidant marker useful for phytochemical standardization
-------------	---------------	---

V. QUALITY-BY-DESIGN RELEVANCE IN POLYHERBAL DEVELOPMENT

Quality by Design is essential in polyherbal research because botanical material varies with species, geography, season, plant part, drying, particle size, extraction solvent and storage. Without quality control, biological results may reflect uncontrolled material variability rather than true pharmacological action. A QbD system converts such variability into critical quality attributes, critical material attributes, critical process parameters and a control strategy.

Quality by Design Control Strategy



Original schematic prepared for thesis drafting; replace with final approved figure if required.

Figure 3. QbD and standardization control strategy for the polyherbal formulation.

Table 3. QbD considerations for hepatoprotective polyherbal formulation

QbD element	Application	Scientific importance
QTPP	Safe and reproducible oral test formulation	Defines desired product profile
CQA	Identity, purity, marker content, dose uniformity, microbial quality	Links quality to safety and biological interpretation
CMA	Plant source, part used, drying, particle size, solvent quality	Controls raw material variability
CPP	Extraction time, temperature, solvent ratio, mixing and drying	Controls process-dependent variation
Control strategy	Specifications, batch records, stability and storage controls	Supports reproducibility and scale-up

VI. PRECLINICAL EVALUATION ENDPOINTS

The validity of hepatoprotective interpretation depends on selecting endpoints that reflect the known toxicological pathway. Serum transaminases alone are insufficient because they indicate membrane leakage but not necessarily oxidative restoration or tissue preservation. A stronger study combines biochemical liver markers, antioxidant status, inflammatory or cytokine measures where available, histology and statistical analysis.

Serum ALT and AST are primary indicators of hepatocellular leakage.

ALP and bilirubin help assess excretory or cholestatic stress.

MDA reflects lipid peroxidation and oxidative membrane damage.

GSH, SOD, catalase and GPx indicate endogenous antioxidant defense.

Copyright to IJARSCT

www.ijarsct.co.in



DOI: 10.48175/IJARSCT-37813



Histopathology confirms whether biochemical improvement is supported by tissue preservation.
Body weight and behavioral observations support general safety and tolerability interpretation.

VII. SAFETY AND TRANSLATIONAL LIMITATIONS

A major limitation in polyherbal hepatoprotection is the possibility of assuming clinical efficacy from preclinical trends. Protective activity in a rodent paracetamol model does not automatically establish clinical benefit. Toxicity, herb-drug interaction potential, batch variability, bioavailability, dose selection and chronic exposure must be evaluated before translation.

Another limitation is the use of representative graphs or expected trends in early dissertation drafts. Such material is useful for planning but cannot replace verified laboratory readings. A manuscript should clearly distinguish actual observations from planned or template data, and should include exact statistical outputs and photomicrographic evidence before submission.

VIII. FUTURE PERSPECTIVES

Future work should integrate chromatographic fingerprinting, simultaneous marker estimation, acute and repeated-dose toxicity studies, cytokine profiling, mitochondrial markers, protein expression studies and computational analysis. If preclinical results are consistent and reproducible, clinical translation should proceed only through well-designed controlled studies with safety monitoring.

IX. CONCLUSION

Paracetamol-induced liver injury provides a mechanistically coherent model for evaluating hepatoprotective interventions. Polyherbal formulations may be valuable when their phytochemical complexity is controlled through authentication, standardization, QbD planning and rigorous endpoint selection. The strongest evidence will arise from concordant improvement in serum enzymes, oxidative stress markers and histopathology, supported by transparent reporting and validated quality controls.

REFERENCES

- [1]. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. *Phytother Res.* 2010;24:1423-1432.
- [2]. Aebi H. Catalase in vitro. *Methods Enzymol.* 1984;105:121-126.
- [3]. Agrawal S, Khazaeni B. Acetaminophen Toxicity. StatPearls. Treasure Island: StatPearls Publishing; 2025.
- [4]. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury. *Hepatology.* 2013;58:777-787.
- [5]. Bajt ML, Knight TR, Lemasters JJ, Jaeschke H. Acetaminophen-induced oxidant stress and cell injury. *Toxicol Sci.* 2004;80:343-349.
- [6]. Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for prediction of toxicity of chemicals. *Nucleic Acids Res.* 2018;46:W257-W263.
- [7]. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. *Nucleic Acids Res.* 2000;28:235-242.
- [8]. Bjornsson ES. Hepatotoxicity by drugs: the most common implicated agents. *Int J Mol Sci.* 2016;17:224.
- [9]. Buege JA, Aust SD. Microsomal lipid peroxidation. *Methods Enzymol.* 1978;52:302-310.
- [10]. CCSEA/CPCSEA. Compendium of guidelines for laboratory animal experimentation. Government of India.
- [11]. Chakote VR, Dhembre GN, Rajguru JR, Joshi DA. In-Situ Gel for Nasal Drug Delivery. *International Journal of Development Research.* 2018;8(2):18763-18769.
- [12]. Chun LJ, Tong MJ, Busuttill RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. *J Clin Gastroenterol.* 2009;43:342-349.



- [13]. Dahlin DC, Miwa GT, Lu AYH, Nelson SD. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. *Proc Natl Acad Sci U S A*. 1984;81:1327-1331.
- [14]. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics and drug-likeness. *Sci Rep*. 2017;7:42717.
- [15]. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. *Clin Chem*. 2006;52:601-623.
- [16]. Dhamale GR, Shinde PB, Rajguru JR. A Review: Gastroretentive Drug Delivery Systems. *International Journal of Pharmaceutical Sciences*. pp.1825–1840. doi:10.5281/zenodo.12818744.
- [17]. Dinarello CA. Anti-inflammatory agents: present and future. *Cell*. 2010;140:935-950.
- [18]. Doke R, Rajguru J, Vinchurkar K. Personalized Medicine Through AI-Driven Imaging. In: *Springer Nature*. doi:10.1007/978-3-032-02963-8_7.
- [19]. Du K, Ramachandran A, Jaeschke H. Oxidative stress during acetaminophen hepatotoxicity. *Redox Biol*. 2016;10:148-156.
- [20]. Ellman GL. Tissue sulfhydryl groups. *Arch Biochem Biophys*. 1959;82:70-77.
- [21]. Federico A, Dallio M, Loguercio C. Silymarin and silybin in liver disease. *World J Gastroenterol*. 2017;23:8381-8390.
- [22]. Fontana RJ. Acute liver failure including acetaminophen overdose. *Med Clin North Am*. 2008;92:761-794.
- [23]. Gadekar SN, Rajguru JR, Biyani KR. Review on Solid Dispersion for Suitable Drug. *World Journal of Pharmaceutical Sciences*. 2021;9(9):230–235.
- [24]. Gawai NM, Jadhav RR, Modak A, Sawarkar HS, Rajguru JR. Advancements in Nanogel Technology for Drug Delivery: Current Innovations and Future Perspectives. *African Journal of Biomedical Research*. 2024;27(3S):3200–3212. doi:10.53555/AJBR.v27i3S.2905.
- [25]. Gawari PB, Rajguru JR. Confronting the Nipah Virus: Critical Insights and Practical Recommendations. *International Journal of Creative Research Thoughts (IJCRT)*. 2026;14(2). ISSN: 2320-2882.
- [26]. Ghosh MN. Fundamentals of Experimental Pharmacology. 6th ed. Kolkata: Hilton; 2015.
- [27]. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. *Drug Saf*. 2005;28:227-240.
- [28]. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 5th ed. Oxford: Oxford University Press; 2015.
- [29]. Hanawa N, et al. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. *J Biol Chem*. 2008;283:13565-13577.
- [30]. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods*. 2017;6:92.
- [31]. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. *Handb Exp Pharmacol*. 2010;196:369-405.
- [32]. Imaeda AB, Watanabe A, Sohail MA, et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. *J Clin Invest*. 2009;119:305-314.
- [33]. Ingole RD, Gawai NM, Rajguru JR. Nanoformulation of Vitamin D Derivatives and Metabolites. *African Journal of Biomedical Research*. 2024;27(4S). doi:10.53555/AJBR.v27i4S.4897.
- [34]. JRajguru R. Development and Validation of RP-HPLC and UV Spectrophotometric Absorptivity Method for Simultaneous Estimation of Cyclobenzaprine Hydrochloride and Aceclofenac in Pharmaceutical Dosage Form. *International Journal of Science & Engineering Development Research*. 2020;5(4):320–329.
- [35]. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. *Toxicol Sci*. 2002;65:166-176.
- [36]. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. *Drug Metab Dispos*. 2003;31:1499-1506.
- [37]. Jeevan Rajguru R. Magnetic and pH Sensitive Nanoparticles for Cancer Drug Delivery. *Asian Journal of Pharmaceutical Research and Development*. 2019;7(4).



- [38]. JR.Rajguru Biomarkers and Diagnostics. *International Journal of Scientific Development and Research*. 2020;5(4).
- [39]. JR. Rajguru Development and Evaluation of Nasal Mucoadhesive In-Situ Gel Formulations of Carbamazepine Using In-Vitro, Ex-Vivo and In-Vivo Methods. *International Research Journal of Pharmacy and Medical Sciences*. 2018;1(6).
- [40]. Kaplowitz N. Drug-induced liver injury. *Clin Infect Dis*. 2004;38 Suppl 2:S44-S48.
- [41]. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol*. 2005;5:749-759.
- [42]. Kim S, et al. PubChem 2023 update. *Nucleic Acids Res*. 2023;51:D1373-D1380.
- [43]. King EJ, Armstrong AR. A convenient method for determining serum and bile phosphatase activity. *Can Med Assoc J*. 1934;31:376-381.
- [44]. Kon K, Kim JS, Jaeschke H, Lemasters JJ. Mitochondrial permeability transition in acetaminophen-induced necrosis. *Hepatology*. 2004;40:1170-1179.
- [45]. Kshirsagar A, et al. Hepatoprotective effect of medicinal plants: a review. *Pharmacogn Rev*. 2009;3:116-124.
- [46]. Kushwah P, Rajguru JR, Jain G, Patidar A, Tomar PS. A Review of Classic Cures for Contemporary Marvels: Unveiling the Medicinal Secrets of *Piper betle* Linn. Leaves and *Nyctanthesarbor-tristis*. *International Journal of Creative Research Thoughts (IJCRT)*. 2024;12(1)-D747.
- [47]. Larson AM. Acetaminophen hepatotoxicity. *Clin Liver Dis*. 2007;11:525-548.
- [48]. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb Perspect Biol*. 2009;1:a001651.
- [49]. Lee WM. Drug-induced hepatotoxicity. *N Engl J Med*. 2003;349:474-485.
- [50]. Li S, et al. Picrorhizakurroa and picrosides: phytochemistry and pharmacology. *Fitoterapia*. 2020;142:104519.
- [51]. Liao J, et al. Acetaminophen-induced liver injury: molecular mechanism and treatment. *Front Pharmacol*. 2023;14:1122632.
- [52]. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability. *Adv Drug Deliv Rev*. 2001;46:3-26.
- [53]. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. *Gastroenterology*. 2004;127:1760-1774.
- [54]. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. *J Biol Chem*. 1951;193:265-275.
- [55]. Luo G, et al. Molecular mechanisms of acetaminophen-induced liver injury. *Front Pharmacol*. 2023;14:1184070.
- [56]. Marklund S, Marklund G. Involvement of superoxide anion radical in autoxidation of pyrogallol and a convenient assay for superoxide dismutase. *Eur J Biochem*. 1974;47:469-474.
- [57]. Mazaleuskaya LL, Sangkuhl K, Thorn CF, FitzGerald GA, Altman RB, Klein TE. Pathways of acetaminophen metabolism at therapeutic and toxic doses. *Pharmacogenet Genomics*. 2015;25:416-426.
- [58]. McGill MR, et al. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment. *Toxicol Appl Pharmacol*. 2012;264:387-394.
- [59]. McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: recent advances. *Pharm Res*. 2013;30:2174-2187.
- [60]. Medzhitov R. Origin and physiological roles of inflammation. *Nature*. 2008;454:428-435.
- [61]. Mirochnitchenko O, et al. Acetaminophen toxicity: opposite effects of two forms of glutathione peroxidase. *J Biol Chem*. 1999;274:10349-10355.
- [62]. Mishra K, et al. Pharmacological activity of andrographolide: a review. *Indian J Pharm Sci*. 2013;75:1-9.



- [63]. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. *J Pharmacol Exp Ther.* 1973;187:185-194.
- [64]. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal.* 2014;20:1126-1167.
- [65]. Motulsky H. *Intuitive Biostatistics*. 4th ed. New York: Oxford University Press; 2018.
- [66]. Nathan C. Points of control in inflammation. *Nature.* 2002;420:846-852.
- [67]. National Institute of Diabetes and Digestive and Kidney Diseases. Acetaminophen. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda: NIH; 2016.
- [68]. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. *Semin Liver Dis.* 1990;10:267-278.
- [69]. OECD. Test Guideline 423: Acute Oral Toxicity - Acute Toxic Class Method. Paris: OECD Publishing; 2001.
- [70]. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem.* 1979;95:351-358.
- [71]. Paglia DE, Valentine WN. Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med.* 1967;70:158-169.
- [72]. Pastorino G, Cornara L, Soares S, Rodrigues F, Oliveira MBPP. Glycyrrhiza glabra: a phytochemical and pharmacological review. *Phytother Res.* 2018;32:2323-2339.
- [73]. Patel JR, Tripathi P, Sharma V, Chauhan NS, Dixit VK. Phyllanthus amarus: ethnomedicinal uses, phytochemistry and pharmacology. *J Ethnopharmacol.* 2011;138:286-313.
- [74]. Prescott LF. Paracetamol overdose: pharmacological considerations and clinical management. *Drugs.* 1983;25:290-314.
- [75]. RRajguru J. Gene Therapy – Challenges & Success. *International Journal of Trend in Scientific Research and Development.* 2020;4(3).
- [76]. Rajguru JR, Gawari PB, Desai RS, Isal AA. Overview of Intrauterine Drug Delivery System. *International Journal of Creative Research Thoughts (IJCRT).* 2024;12(1)–D316.
- [77]. Rajguru JR, Navghare AB, Shinde SP, Pawar PP, Lokhande PB. An Overview of Implantable Drug Delivery Systems. *International Journal of Creative Research Thoughts (IJCRT).* 2024;12(1)–F958.
- [78]. Rajguru JR, Shinde PB, Shinde SP, Humbe KA, Pawar PP. Nasal Routes of Drug Delivery: A Creative Approach. *International Journal of Creative Research Thoughts (IJCRT).* 2024;12(1)–E477.
- [79]. Rajguru JR, Shirsat MK. Development of the Formulation and Evaluation of the Anti-Arthritic Activity of *Vitex negundo* Gel and Latex. *International Journal of Drug Delivery Technology.* 2023;13(1).
- [80]. Rajguru JR, Shirsat MK. Development of the Formulation and Evaluation of the Anti-Inflammatory Activity of *Vitex negundo* Gel and Latex. *International Journal of Pharmaceutical Quality Assurance.* 2023;14(1).
- [81]. Rajguru JR. A Review – Corona Virus (COVID-19). *International Journal of Science and Engineering Development Research.* 2020;5(4):1–6.
- [82]. Rajguru JR. A Review on: Mucormycosis. *International Journal of Innovative Research in Technology.* 2021;8(1):323–330.
- [83]. Rajguru JR. Cancer Chemotherapy with Peptides and Peptidomimetics Drug and Peptide-Based Vaccines. *International Research Journal of Pharmacy and Medical Sciences.* 2019;2(2).
- [84]. Rajguru JR. Novel Drug Delivery System in Recent Trends as Carrier. *World Journal of Pharmacy and Pharmaceutical Sciences.* 2020;9(5):193–205. doi:10.20959/wjpps20205-15995.
- [85]. Ramachandran A, Jaeschke H. Acetaminophen toxicity: novel insights into mechanisms and future perspectives. *Gene Expr.* 2018;18:19-30.
- [86]. Ramachandran A, Jaeschke H. Role of mitochondria in acetaminophen hepatotoxicity. *Cells.* 2023;12:1155.



- [87]. Reitman S, Frankel S. A colorimetric method for determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. *Am J Clin Pathol*. 1957;28:56-63.
- [88]. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. *ArteriosclerThrombVasc Biol*. 2011;31:986-1000.
- [89]. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. *Pediatrics*. 1975;55:871-876.
- [90]. Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and AutoDock/Vina. *J Comput Aided Mol Des*. 2010;24:417-422.
- [91]. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. *Nat Immunol*. 2005;6:1191-1197.
- [92]. Sies H. Oxidative stress: a concept in redox biology and medicine. *Redox Biol*. 2015;4:180-183.
- [93]. Sitaphale GR, Tathe PR, Laddha PR, Charhate KB, Rajguru JR. Phytochemical Screening, Isolation, and Characterization of Extract from Various Parts of *Phoenix sylvestris*. *African Journal of Biomedical Research*. 2024;27(3S):3368–3374. doi:10.53555/AJBR.v27i3S.2938.
- [94]. Tathe PR, Laddha PR, Sitaphale GR, Charhate KB, Pimple UA, Jadhao YD, Alhat RM, Rajguru JR. Studies in Preparation and Evaluation of Nanoparticles for Controlled Drug Delivery of Peptide-Based Drugs. *African Journal of Biomedical Research*. 2024;27(3S):3179–3190. doi:10.53555/AJBR.v27i3S.2894.
- [95]. Teschke R, Danan G. Drug induced liver injury: causality assessment methods. *Front Pharmacol*. 2019;10:853.
- [96]. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. *Anal Biochem*. 1969;27:502-522.
- [97]. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking. *J Comput Chem*. 2010;31:455-461.
- [98]. Turner RA. Screening Methods in Pharmacology. New York: Academic Press; 1965.
- [99]. U.S. Food and Drug Administration. Acetaminophen information for consumers and health professionals. Silver Spring: FDA; 2025.
- [100]. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol*. 2007;39:44-84.
- [101]. Vogel HG. Drug Discovery and Evaluation: Pharmacological Assays. Berlin: Springer; 2015.
- [102]. Wayal SR, Barke SA, Darekar SM, Jalindar AS, Gawai NM, Wankhede HR, Bathe RS, Rajguru JR. Development of Currant-Loaded Nanoparticles and Phytosomes for Enhanced Antioxidant Delivery. *International Journal of Environmental Sciences*. 2025;11(22S):4067–4071. doi:10.64252/p2tec31.
- [103]. Wayal SR, Darekar SM, Jalindar AS, Motr PR, Gawai NM, Bodake PL, Barke SA, Dongare AB, Rajguru JR. Development of a Validated HPTLC Method for the Simultaneous Estimation of Curcumin and Berberine in DashamoolaKvatha. *International Journal of Environmental Sciences*. doi:10.64252/kq9rtn45.
- [104]. Wayal SR, Rajguru JR, Bhise MR. A Systematic Review on the Effective Teaching Strategies and Methods for Cancer Patient Education. *Journal of Cancer Education*. 2025. doi:10.1007/s13187-025-02759-z.
- [105]. Woolbright BL, Jaeschke H. Role of the inflammasome in acetaminophen-induced liver injury. *Food Chem Toxicol*. 2017;105:76-85.
- [106]. Yan M, et al. Mechanisms of acetaminophen-induced liver injury and implications for therapeutic interventions. *Redox Biol*. 2018;17:274-283.
- [107]. Yoon E, Babar A, Choudhary M, Kutner M, Pysopoulos N. Acetaminophen-induced hepatotoxicity: a comprehensive update. *J Clin Transl Hepatol*. 2016;4:131-142.

